# A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

> **NCT05527912** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 45 (estimated)

## Conditions studied

- Double Express Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

## Key facts

- **NCT ID:** NCT05527912
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-24
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05527912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05527912, "A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05527912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*